Status:
COMPLETED
"Clinical and Epidemiological Characteristics of Inflammatory Rhinitis in Patients on Biotherapies"
Lead Sponsor:
Nantes University Hospital
Conditions:
Inflammatory Rhinitis
Eligibility:
All Genders
18+ years
Brief Summary
Inflammatory rhinitis is a side effect observed in patients treated with biotherapies in the context of chronic bowel disease (IBD) or spondylartrhopathy (SPA). This damage is still poorly described i...
Detailed Description
Inflammatory rhinitis is a side effect observed in patients treated with biotherapies in the context of chronic bowel disease (IBD) or spondylartrhopathy (SPA). This damage is still poorly described i...
Eligibility Criteria
Inclusion
- Adult patient (\> 18 years of age),
- Biotherapy treatment: anti TNF, ustekinumab, secukinumab, ixekizumab, Rituximab, vedolizumab, abatacept, inhibitor jak kinase, anti Il1, Anti Il6,
- Biotherapy treatment \> 3 months,
- Chronic inflammatory disease: psoriasis, ankylosing spondylitis (SPA), rheumatoid arthritis (RA), Crohn's disease (CD), bleeding rectocolitis (HRC)
- No opposition to the study
Exclusion
- Patient under legal protection measure,
- Refusal of the subject to participate in the study,
Key Trial Info
Start Date :
November 19 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 19 2020
Estimated Enrollment :
356 Patients enrolled
Trial Details
Trial ID
NCT04132258
Start Date
November 19 2019
End Date
June 19 2020
Last Update
June 8 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital
Nantes, France